ERN1 and triple-negative breast carcinoma: Inhibition of IRE1 RNase activity has been shown to exert beneficial effects as either a standalone treatment or in combination with chemotherapeutics in pre-clinical models of triple negative breast cancer (TNBC) and prostate cancer [360,361,362].